Xiaoming Zou
Chief Executive Officer Visirna Therapeutics
Seminars
Thursday 10th December 2026
Clinical Development Progress of VSA012, an siRNA Molecule Targeting CFB
12:00 pm
- VSA012 profile, a highly potent and selective inhibitor of CFB
- Phase 2 data of in PNH in naïve and refractory patients
- Preliminary data in IgAN for VSA012
NEW SPEAKING COMPANY
